Empagliflozin Crystalline anhydrous
Product Description
Polpharma S.A.
-
PL
-
2015On CPHI since
-
4Certificates
-
5000+Employees
Company types
Specifications
Polpharma S.A.
-
PL
-
2015On CPHI since
-
4Certificates
-
5000+Employees
Company types
More Products from Polpharma S.A. (34)
-
Product Rivaroxaban
Rivaroxaban
MODIFICATION I
> No risk of presence of nitrosamines
> Innovative crystalization obtaining material of high purity
CEP,
US DMF,
CHINESE DMF,
KOREAN DMF
DISCLAIMER ... -
Product Trametinib
Trametinib
DMSO solvate
Oncology
OEB 5
DISCLAIMER
Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes patent infringement. It is within the buyer’s responsibility and liability... -
Product Zoledronic Acid
Zoledronic Acid
Monohydrate
> No risk of presence of nitrosamines
> Long experience with commercial manufacturing
> In-house production of the whole product family (Risedronate, Alendronate, Ibandronate)
... -
Product Piracetam
Piracetam
Form II
> Capacity and flexibility to cover high-volume demand
oral & injectable forms
CEP,
BRAZILIAN DMF"
DISCLAIMER
Products protected by valid patents are not offered for sale in cou... -
Product Linagliptin
Linagliptin
Mix A&B
> White API color
> Better impurity profile
DISCLAIMER
Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes patent infringement. It ... -
Product Elagolix sodium Amorphous form
DISCLAIMER
The above product is presented solely for informational purposes and does not constitute an offer in any sense. Products with PIPELINE & EARLY DEVELOPMENT STATUS under patent (SPC) protection in Poland and/or other countries are not offered until expiration of the corresponding IP... -
Product Linagliptin Mix of form A & B
DISCLAIMER
The above product is presented solely for informational purposes and does not constitute an offer in any sense. Products with PIPELINE & EARLY DEVELOPMENT STATUS under patent (SPC) protection in Poland and/or other countries are not offered until expiration of the corresponding IP... -
Product Pimavanserin tartrate Crystalline anhydrous form C
DISCLAIMER
The above product is presented solely for informational purposes and does not constitute an offer in any sense. Products with PIPELINE & EARLY DEVELOPMENT STATUS under patent (SPC) protection in Poland and/or other countries are not offered until expiration of the corresponding IP... -
Product Rivaroxaban
DISCLAIMER
The above product is presented solely for informational purposes and does not constitute an offer in any sense. Products with PIPELINE & EARLY DEVELOPMENT STATUS under patent (SPC) protection in Poland and/or other countries are not offered until expiration of the corresponding IP... -
Product Sitagliptin hydrochloride Polymorphic form III
DISCLAIMER
The above product is presented solely for informational purposes and does not constitute an offer in any sense. Products with PIPELINE & EARLY DEVELOPMENT STATUS under patent (SPC) protection in Poland and/or other countries are not offered until expiration of the corresponding IP... -
Product Isavuconazole sulfate
DISCLAIMER
The above product is presented solely for informational purposes and does not constitute an offer in any sense. Products with PIPELINE & EARLY DEVELOPMENT STATUS under patent (SPC) protection in Poland and/or other countries are not offered until expiration of the corresponding IP... -
Product Enzalutamide
We provide with Anhydrous form R1
Enzalutamide is a second-generation androgen receptor inhibitor used to treat castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer. Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of c...
Polpharma S.A. resources (2)
-
News CPHI Barcelona 2023: Tackling the Pharma Talent Precipice – Part 2
This year at CPHI Barcelona (24–26 October, 2023) we sat down with C-suite executives and HR professionals to discuss the looming talent crisis in the pharmaceutical industry. With hybrid working persisting post-pandemic and a growing skills gap, how can the pharmaceutical supply chain adjust to a changing labour force? -
Brochure API Product List 2024
We manufacture our products by following our customers' and health authorities' most stringent requirements. DMF documentation for all our products is prepared in accordance with the latest requirements of EDQM (CEP), ICH (EuDMF, CTD), and FDA (US DMF). Material and product testing is performed in line with the European and United States Pharmacopeias.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance